EUCTR2006-000366-36-BE进行中（未招募）不适用
Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer - ASSIST-5
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Telik, Inc.
- 入组人数
- 244
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Considered platinum refractory or resistant according to standard criteria.
- •2. Histologically or cytologically confirmed epithelial cancer of the ovary, fallopian tube or primary peritoneal cancer.
- •3. Measurable disease including at least one measurable lesion according to RECIST criteria with documented tumor progression before study entry or disease that has not responded to treatment.
- •4. Female = 18 years of age.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Treatment with chemotherapy other than a platinum-based regimen.
- •2. Treatment with more than two platinum-based regimens.
- •3. Clinically significant cardiac disease.
- •4. Any signs of intestinal obstruction interfering with nutrition.
- •5. Pregnant or lactating women.
- •6. History of prior liposomal doxorubicin or anthracycline chemotherapy for ovarian cancer.
- •7. History of prior TLK286 (Telcyta™) therapy.
研究者
相似试验
进行中（未招募）
1 期
Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer - ASSIST-5EUCTR2006-000366-36-GBTelik, Inc.244
进行中（未招募）
不适用
A Clinical Trial to Compare the Effectiveness of TLK286 (Telcyta?) and Gefitinib (Iressa®) in Non-Small Cell Lung Canceron-small cell lung cancer, including squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with squamous cell carcinoma) or large cell carcinoma, recurrent or resistant following two prior chemotherapy regimens which must have included a platinum agent (carboplatin or cisplatin).MedDRA version: 14.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-000330-36-ESTelik, Inc.530
已完成
3 期
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian CancerOvarian NeoplasmsNCT00057720Telik440
进行中（未招募）
不适用
Phase 3 Randomized Study of TLK286 versus Gefitinib(Iressa) as Third-Line Therapy in Locally Advanced orMetastatic Non-Small Cell Lung CancerTreatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.EUCTR2004-000330-36-ITTELIK, INC.520
已完成
3 期
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian CancerOvarian NeoplasmsNCT00102973Telik244